whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation

See FDA's updated safety analysis concerning bisphophonates and atrial fibrillation

Patients are asking whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation.

This first came up last year when researchers noted an increase in A fib in patients getting zoledronic acid (Reclast).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote